Skip to main content
. Author manuscript; available in PMC: 2012 Mar 26.
Published in final edited form as: Cancer. 2011 Feb 1;117(15):3468–3475. doi: 10.1002/cncr.25928

Table 2.

Patient Outcomes (N = 41)

Outcome Frequency/Estimate
Response ratea 5% (95% CI, 1–17)
No. of responders (PR) 2
Time to response, median mo 2.7 mo (range, 2–4)
Overall survival, median mob 7.6 mo (95% CI, 6.1–15.9)
 6 months 66% (95% CI, 53–82)
 12 months 39% (95% CI, 27–57)
 18 months 34% (95% CI, 22–52)
Time to disease progression, median mob 2.0 (95% CI, 1.8–3.5)
 2 months 54% (95% CI, 41–72)
 3 months 41% (95% CI, 28–60)
 4 months 22% (95% CI, 12–40)
6 months 13% (95% CI, 6–31)

CI indicates confidence interval; PR, partial response.

a

n = 40; response sustained for at least 2 consecutive evaluations.

b

Kaplan-Meier method.